MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
Year: 2021
Type: article
Study design: Clinical Trial
Source: Journal of Thoracic Oncology
Institutions: Severance Hospital, Yonsei Cancer Hospital, University of Colorado Anschutz, University of Colorado Denver, Harvard University, Massachusetts General Hospital, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Seattle Cancer Care Alliance, University of Washington, Fred Hutch Cancer Center, University Medical Center Groningen, University of Groningen, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Chungbuk National University Hospital, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Peter MacCallum Cancer Centre, Chris O’Brien Lifehouse, University of Manchester, The Christie NHS Foundation Trust, University of California, Irvine, Memorial Sloan Kettering Cancer Center, Cornell University, Weill Cornell Medicine
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3136059866